Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients
Alejandro Contreras(Baylor College of Medicine), MF Rimawi, Jae C. Chang, Carlos Gutiérrez(Beth Israel Deaconess Medical Center), Sabrina Herrera(Mayo Clinic), T Wang(Mayo Clinic), Rachel Schiff(Baylor College of Medicine), Andres Forero(University of Alabama at Birmingham), MM Li(Mayo Clinic), Ingrid A. Mayer(Vanderbilt University), AC Pavlick, CK Osborne(Mayo Clinic), Rita Nanda(University of Chicago), SG Hilsenbeck(Beth Israel Deaconess Medical Center), Matthew P. Goetz(Mayo Clinic)
Cited by 18
Related Papers
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
|npj Breast Cancer|2019|673